CTSS and lung disorder: In a recent study using the βENaC-transgenic mouse model of CF lung disease, pharmacological or genetic targeting of CTSS decreased inflammation and mucus plugging in the lungs mediated, at least in part, via inhibition of PAR2 suggesting a potential novel therapeutic avenue for CF [73].